Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com
Simplified Gout Remission Definition Feasible, Valid
Remission according to the simplified definition correlated with the 2016 preliminary gout remission definition and GIS score improvements.
Read More
Blue Shield California Offers Adalimumab Biosimilar for a Quarter of Reference Price
BSC and Fresnius Kabi reached a deal facilitated by Evio Pharmacy Solutions by sidestepping pharmacy benefit managers.
Ixekizumab as Effective, if not More Effective as TNFi, JAKi, IL-12/23i for PsA Treatment
An interim analysis of the PRO-SPIRIT study compared outcomes at 3 months after starting new treatments for psoriatic arthritis.
Biosimilars Month in Review: September 2024
The biosimilars month in review highlights a new approval and 2023 cost savings
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
Mease discussed the importance of comparator studies in a growing treatment landscape for PsA.
Rheumatology Month in Review: September 2024
The rheumatology month in review emphasizes new trends in medication use and novel technologies' potential for managing fibromyalgia.
Dupilumab Improves Sleep, Itch, and Other QoL Measures in Children With Eczema
A new post-hoc analysis has also revealed improvements in quality of life in patients’ caregivers.
Early Antibiotic Treatment Associated With Atopic Dermatitis, Asthma
Further research is needed to understand the mechanism behind the link as antibiotic exposure is often necessary in care.
Faster Weight Loss on Anti-Obesity Medication Correlated With Lower Risk of Gout
Compared with participants who gained weight or who weight remained stable, the risk of developing gout fell with increased weight loss over 1 year.
Rapid, High-Fidelity Medical Imaging Reveals Cancer, Arthritis in New Research
The all-optical PAT scanner reduces acquisition time from minutes to seconds and can visualize microvasculature changes to depths approaching 15 mm.
Early Rheumatoid Arthritis Characteristics Have Changed Over Last 20 Years
More research is needed to investigate changing trends at presentation and help to inform current treatment strategies.
New Research Identifies Predictive Changes in Joint Microenviroment Prior to RA Onset
The data also support the validity of further research into targeting CD-40 signaling in patients with RA not responding to treatment.
Bimekizumab Improves Pain, Fatigue, and More in Active Psoriatic Arthritis Over Placebo
A greater portion of patients treated with bimekizumab achieved minimal clinically important differences than with placebo.
FDA Approves Stelara Biosimilar Ustekinumab-aauz (Otulfi)
The approval marks the fourth biosimilar approved for ustekinumab, for all approved indications.
Service Members Often Fail to Receive Suitable Follow-up Care for Fibromyalgia
Received care was highly variable among ethnicities and gender and often contradicted current guidelines.
Study Finds Greater Pain Reduction With JAKis Over bDMARDs in Third-Line RA
In other populations, JAKis demonstrated at least a similar pain benefit to b/tsDMARDs from baseline.
Biosimilars Saved $12.3 Billion in 2023, a Fraction of Potential Savings
To date, biosimilars have supported 495 million incremental days of therapy that patients would otherwise not have received.
Considering Viral Infections in Patients With Rheumatic Disease, with Leonard Calabrese, DO
Calabrese discussed factors for rheumatologists to keep in mind, including recent travel and screening for viral infections.
Higher Cardiovascular Health Reduced Risk of Gout
Higher Life’s Essential 8 score was associated with higher CVH scores in US adults.
ULT Therapy Adherence High for Gout, Nonadherence Increases Flares
Younger people and people without European origin were less likely to adhere to urate-lowering therapy.
Ertugliflozin Lowers UA, Improves Gout Outcomes in People With Type 2 Diabetes and ASCVD
There were no differences in the treatment effect of ertugliflozin on gout-related outcomes in subgroups based on eric acid quintile or other baseline characteristics.
Inebilizumab Improved Outcomes Over Placebo in Phase 3 Trials for IgG4-RD, Myasthenia Gravis
Further data will be presented at the 2024 AANEM Meeting in Georgia in October.
Dapirolizumab Pegol Meets Primary Endpoint in Phase 3 Study for SLE
The therapy demonstrated superior efficacy in combination with SOC over SOC alone.
Opioid Use Trends Down in Last Decade for Rheumatic Diseases
Concomitantly, other treatment modalities such as physical and occupational therapy, anticonvulsants, topical analgesics, and psychosocial treatment have increased.
The Role of Virology in Rheumatic Disease, with Leonard Calabrese, DO
Calabrese discussed the multi-faceted role of viral infections in the field of rheumatology ahead of the 2024 CCR West meeting.
Bimekizumab Approved for Psoriatic Arthritis, Ankylosing Spondylitis, AxSpA
BIMZELX was previously approved for treating moderate-to-severe plaque psoriasis.
Weather Only Has Small Impact on Psoriatic Arthritis Symptoms
Gender, age, and disease duration significantly affected symptom variations.
Arthritis Incidence in Psoriasis Higher Than EHR Records Suggest
Extended follow-up with more cases is ongoing and will allow risk factors for psoriatic arthritis to also be further explored.
AI Language Model Distinguishes Fibromyalgia From Other Chronic Pain Conditions
The model gave special emphasis to words noting pain, fatigue and depressed moods.
Gout Prevalence to Increase by More Than 70% by 2050
The increase will largely be driven by population growth and aging.